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OBJECTIVES: To aid interpretation of scores on the Living with
COPD scale (LCOPD; scored 0–22), COPD and Asthma Sleep
Impact Scale (CASIS; scored 0–100) and COPD and Asthma
Fatigue Scale (CAFS, scored 0–100). These new patient reported
outcome measures, designed for use in clinical trials, have previ-
ously been shown to be reliable and valid.METHODS:Question-
naire data from UK (n = 162; 46% male; mean age = 69.3 years)
and US (n = 145; 51% male; mean age = 71.7 years) surveys were
analysed. Mean questionnaire scores were evaluated against cli-
nician severity rating and by exacerbation status (US only). Effect
sizes (ES) and standard errors of measurement (SEM)were used to
provide a preliminary estimate of the minimal important dif-
ference (MID). RESULTS: Scores on the LCOPD and CAFS
were signiﬁcantly related to clinician rating of COPD severity
(p < 0.001). A similar trend for the CASIS was not statistically
signiﬁcant. Scores on all measures were also signiﬁcantly higher
(p < 0.05), indicating greater impairment if the patient had had an
exacerbation in the previous week. For the LCOPD the values for
0.3 ES, 0.5 ES and SEMwere 2.0, 3.3 and 1.4 respectively. For the
CASIS the ﬁgures were 7.4, 12.3 and 7.4 and for the CAFS; 7.3,
12.2 and 5.5. Therefore, these distribution-based analyses suggest
that the MID is in the region of 2 for the LCOPD and 7 for the
CASIS and CAFS. CONCLUSIONS: The analyses provide pre-
liminary information on how to interpret scores on the scales.
Further analyses of longitudinal data are required to conﬁrm these
ﬁndings, to assess anchor-based estimates and to allow greater
precision in powering studies using these questionnaires.
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OBJECTIVES: Fatigue experienced by cancer patients need to be
assessed carefully. Yet, there is no agreement on the most appro-
priate recall period to use. In this study, we compared responses
to identical fatigue item pairs, varying only the reporting period
(past 7-days versus past 4-weeks), and explored factors that
inﬂuenced patients’ responses. METHODS: Sample included 216
cancer patients (63.5% female, 80.5% white, mean age = 57.6;
36% had breast cancer). Patients were asked to complete either
a 7-day (n = 100) or 4-week (n = 116) version of the Func-
tional Assessment of Chronic Illness Therapy-Fatigue. Cochran-
Mantel-Haenszel statistics (CMH) and Cochran-Armitage trend
tests were used to assess the association between time frame
and item scores. Information function curves at both item and
scale levels were depicted to evaluate the precision along the
fatigue continuum. Differential item functioning (DIF) was used
to examine the psychometric stability between time frames.
RESULTS: These two sample groups had comparable degree of
fatigue severity at the time of survey (p = 0.209) and at the end of
survey (p = 0.074), as measured with a single 0–10 rating. No
item was rejected by CMH or trend tests at p < 0.01, indicating
that time frame did not inﬂuence patients’ responses. Similarly,
item information curves did not clearly favor either time frame.
No item demonstrated DIF between time frames. Results of
chi-square statistics showed that both gender and fatigue severity
were not signiﬁcantly associated with the time frame patients
reported using to endorse items, p = 0.48 and p = 0.33, respec-
tively. CONCLUSIONS: This study suggests the 7-day and
4-week time frame are equally appropriate in measuring fatigue.
Slight preference might be given to the more informative 7-day
reporting period. However, substantive considerations regarding
the appropriate time frame should outweigh statistical ones.
Comparison of the 7-day time frame to shorter ones (e.g., 24
hour) is needed.
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Organization: Ministry of Health in Poland (MoH), Agency for
Health Technology Assessment in Poland (AHTAPol).
Problem or Issue Addressed: The European Commission (EC)
has pointed out certain areas for improvement in the process of
reimbursement decision—making in Poland, especially in the
ﬁeld of transparency and compatibility with Directive 89/105/
EEC and EC jurisprudence as well as long delays in making
decisions. Moreover the pharmaceutical industry complained
about too long and unclear decision making process. It should
have been improved in areas such as: setting deadlines for taking
decisions; objective and veriﬁable criteria; clear and adequate
information of the decision to applicants; inclusion of expert
opinions in the process of conducting decisions.
Goals: To establish decision—making system, transparent and
clear for all stakeholders and in line with the Transparency
Directive.
Outcomes items used in the decision: In the decisions – making
process on drug reimbursement Poland uses outcomes concern-
ing effectiveness and safety, cost-effectiveness, budget impact
analyses, health priorities and price negotiations.
Implementation Strategy: To solve the above—mentioned prob-
lems an EU Twinning Project between Poland and France was
signed and took place between October 2006 and April 2008.
The European experts analyzed the Polish reimbursement system
and gave recommendations on how to improve it. During the
Project employees of MoH and AHTAPol were sent on study
trips and internships to gain knowledge about other Europeans
systems and work in different institutions involved.
Moreover the several workshops and conferences took place
during and after the EU Project with all involved stakeholders to
set up the best available drug reimbursement decision making
process. During the workshops we used recommendations done
by EU experts as well as other countries experiences. The work-
shops were divided into 3 groups based on their tasks: to identify
reimbursement and pricing criteria; to divide responsibilities
between main actors and to deﬁne role of different stakeholders
involved in the process. The ﬁrst seminar aimed at creating the
momentum in which the necessary political decisions could be
made. During this seminar three Vice-Ministers of the Ministry
of Health conﬁrmed that a new comprehensive Bill on reimburse-
ment decisions would encompass the entire procedure of
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